急性脑梗死患者重组组织型纤溶酶原激活物静脉溶栓后脑出血

重组组织型纤溶酶原激活物(recombinant tissue plasminogen activator,rtPA)静脉溶栓是急性缺血性卒中最有效的治疗手段,其最严重的并发症为有症状脑出血,文献撒道其总体发生率为6%,与血管损伤和通透性增加有关.某些临床特征、影像学和实验室检查可预测脑出血并发症风险.溶栓治疗后发生脑出血并发症的患者病死率和致残率极高,预后很差.文章对溶栓后脑出血的分型、发生率、预测因素和预后进行了综述.

Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator for acute cerebral infarction

Intravenous recombinant tissue plasminogen activator (rtPA) thrombolysis is the most effective therapy for acute ischemic stroke. Its most serious complication is symptomatic intracerebral hemorrhage. The overall incidence reported in the literature is 6%. It is correlated with the wascular injury and the increased vascular permeability. Some clinical features, imaging and laboratory tests can predict the risks of the complication of intracerebral hemorrhage. The mortality and disability are very high in patients with the complications of intracerebral hemorrhage after thrombolytic therapy, and their prognosis is very poor. This article reviews the classification, incidence, predictive factors, and prognosis of intracerebral hemorrhage after thrombolysis.